Doxil® (pegylated liposomal doxorubicin) is a standard chemotherapy drug used in women with ovarian, fallopian tube, or primary peritoneal cancer that persists despite treatment with other chemotherapy, such as paclitaxel and carboplatin. The purpose of this study is to find the highest dose of an investigation drug called VTX-2337 that can be given safely with Doxil in women with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
VTX-2337 works by stimulating the immune system to help the body kill cancer cells. It is an injection given under the skin (subcutaneously). This study is sponsored by the Gynecologic Oncology Group.